{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:10:31Z","timestamp":1790291431002,"version":"4.1.0"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Metastasis to the central nervous system (CNS) is a devastating neurological complication of systemic cancer. Brain metastases from breast cancer have been documented to occur in approximately 10%\u201316% of cases over the natural course of the disease with leptomeningeal metastases occurring in approximately 2%\u20135% of cases of breast cancer. CNS metastases among women with breast cancer tend to occur among those who are younger, have larger tumors, and have a more aggressive histological subtype such as the triple negative and HER2-positive subtypes. Treatment of CNS metastases involves various combinations of whole brain radiation therapy, surgery, stereotactic radiosurgery, and chemotherapy. We will discuss the progress made in the treatment and prevention of breast cancer-associated CNS metastases and will delve into the biological underpinnings of CNS metastases including evaluating the role of breast tumor subtype on the incidence, natural history, prognostic outcome, and impact of therapeutic efficacy.<\/jats:p>","DOI":"10.1634\/theoncologist.2012-0438","type":"journal-article","created":{"date-parts":[[2013,6,6]],"date-time":"2013-06-06T04:59:37Z","timestamp":1370494777000},"page":"675-684","source":"Crossref","is-referenced-by-count":20,"title":["Progress in the Biological Understanding and Management of Breast Cancer-Associated Central Nervous System Metastases"],"prefix":"10.1093","volume":"18","author":[{"given":"Shaheenah","family":"Dawood","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dubai Hospital, Dubai, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Gonzalez-Angulo","sequence":"additional","affiliation":[{"name":"Departments of Breast Medical Oncology and Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,6,5]]},"reference":[{"key":"2021122308322525700_B1","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1158\/1078-0432.CCR-06-2489","article-title":"Targeted therapy for brain metastases: Improving the therapeutic ratio","volume":"13","author":"Patel","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122308322525700_B2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO.2005.04.6235","article-title":"Resectable brain metastases","volume":"24","author":"Vogelbaum","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308322525700_B3","first-page":"54","article-title":"Therapeutic advances in the treatment of brain metastases","volume":"5","author":"Chang","year":"2007","journal-title":"Clin Adv Hematol Oncol"},{"key":"2021122308322525700_B4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0360-3016(00)00547-2","article-title":"Validation of the RTOG recursive partitioning analysis (RPA) classification for the brain metastases","volume":"47","author":"Gaspar","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308322525700_B5","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","article-title":"CNS metastases in breast cancer","volume":"22","author":"Lin","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122308322525700_B6","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdg300","article-title":"Occult central nervous system involvement in patients with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival","volume":"14","author":"Miller","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122308322525700_B7","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B","article-title":"Central nervous system metastasis from breast carcinoma. Autopsy study","volume":"52","author":"Tsukada","year":"1983","journal-title":"Cancer"},{"key":"2021122308322525700_B8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jocn.2010.03.046","article-title":"Surgical treatment for brain metastases: Prognostic factors and survival in 309 patients with regard to patient age","volume":"18","author":"Stark","year":"2011","journal-title":"J Clin Neurosci"},{"key":"2021122308322525700_B9","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/cncr.20530","article-title":"Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment","volume":"101","author":"Gonzalez-Angulo","year":"2004","journal-title":"Cancer"},{"key":"2021122308322525700_B10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdn682","article-title":"Survival of women with triple-receptor negative breast cancer and brain metastases","volume":"20","author":"Dawood","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122308322525700_B11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/00007611-198809000-00011","article-title":"Breast cancer: Metastatic pattern and their prognosis","volume":"81","author":"Patanaphan","year":"1988","journal-title":"South Med J"},{"key":"2021122308322525700_B12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0027-9684(15)31298-0","article-title":"Characteristics of breast cancer patients with central nervous system metastases: A single-center experience","volume":"100","author":"Harputluoglu","year":"2008","journal-title":"J Natl Med Assoc"},{"key":"2021122308322525700_B13","first-page":"867","volume-title":"Diseases of the breast","author":"DeAngelis","year":"2000"},{"key":"2021122308322525700_B14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/pr.57.2.4","article-title":"The blood\u2013brain barrier\/neurovascular unit in health and disease","volume":"57","author":"Hawkins","year":"2005","journal-title":"Pharmacol Rev"},{"key":"2021122308322525700_B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1013104423154","article-title":"Multidrug resistance in brain tumors: Roles of the blood\u2013brain barrier","volume":"20","author":"R\u00e9gina","year":"2001","journal-title":"Cancer Metastasis Rev"},{"key":"2021122308322525700_B16","first-page":"1115","article-title":"Differential permeability of the blood\u2013brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice","volume":"141","author":"Zhang","year":"1992","journal-title":"Am J Pathol"},{"key":"2021122308322525700_B17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cncr.24735","article-title":"Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2\/neu-positive breast cancer","volume":"116","author":"Yonemori","year":"2010","journal-title":"Cancer"},{"key":"2021122308322525700_B18","first-page":"683","article-title":"Changes in blood\u2013brain barrier permeability induced by radiotherapy: Implications for timing of chemotherapy?","volume":"9","author":"Vulpen","year":"2002","journal-title":"Oncol Rep"},{"key":"2021122308322525700_B19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood\u2013brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"2021122308322525700_B20","volume-title":"Lapatinib distribution in brain metastases of breast cancer following oral dosing in mice","author":"Smith","year":"2008"},{"key":"2021122308322525700_B21","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122308322525700_B22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122308322525700_B23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11060-011-0564-y","article-title":"Tissue concentration of systemically administered antineoplastic agents in human brain tumors","volume":"104","author":"Pitz","year":"2011","journal-title":"J Neurooncol"},{"key":"2021122308322525700_B24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nature08021","article-title":"Genes that mediate breast cancer metastasis to the brain","volume":"459","author":"Bos","year":"2009","journal-title":"Nature"},{"key":"2021122308322525700_B25","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122308322525700_B26","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308322525700_B27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/bjc.2011.597","article-title":"Brain metastases free survival differs between breast cancer subtypes","volume":"106","author":"Berghoff","year":"2012","journal-title":"Br J Cancer"},{"key":"2021122308322525700_B28","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/cncr.25771","article-title":"Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: Epidemiological and clinical data from a population-based cancer registry study","volume":"117","author":"Musolino","year":"2011","journal-title":"Cancer"},{"key":"2021122308322525700_B29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-007-9663-z","article-title":"Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: The dark side of the moon? A meta-analysis of the randomized trials","volume":"109","author":"Bria","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"2021122308322525700_B30","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"key":"2021122308322525700_B31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11060-012-0976-3","article-title":"Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery","volume":"110","author":"Vern-Gross","year":"2012","journal-title":"J Neurooncol"},{"key":"2021122308322525700_B32","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.ijrobp.2011.02.027","article-title":"Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases","volume":"82","author":"Sperduto","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308322525700_B33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-009-0057-4","article-title":"The role of steroids in the management of brain metastases: A systematic review and evidence-based clinical practice guideline","volume":"96","author":"Ryken","year":"2010","journal-title":"J Neurooncol"},{"key":"2021122308322525700_B34","first-page":"321","volume-title":"Cancer in the nervous system","author":"Yung","year":"2002","edition":"2nd ed"},{"key":"2021122308322525700_B35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11060-009-0056-5","article-title":"The role of prophylactic anticonvulsants in the management of brain metastases: A systematic review and evidence-based clinical practice guideline","volume":"96","author":"Mikkelsen","year":"2010","journal-title":"J Neurooncol"},{"key":"2021122308322525700_B36","volume-title":"National Comprehensive Cancer Network"},{"key":"2021122308322525700_B37","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A randomized trial of surgery in the treatment of single metastases to the brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N Engl J Med"},{"key":"2021122308322525700_B38","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"2021122308322525700_B39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0360-3016(99)00198-4","article-title":"Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases","volume":"45","author":"Kondziolka","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308322525700_B40","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.280.17.1485","article-title":"Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial","volume":"280","author":"Patchell","year":"1998","journal-title":"JAMA"},{"key":"2021122308322525700_B41","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"2021122308322525700_B42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.radonc.2006.08.004","article-title":"Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05)","volume":"80","author":"Roos","year":"2006","journal-title":"Radiother Oncol"},{"key":"2021122308322525700_B43","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122308322525700_B44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952\u201326001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308322525700_B45","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.radonc.2011.08.041","article-title":"Treatment of brain metastases: Review of phase III randomized controlled trials","volume":"102","author":"Scoccianti","year":"2012","journal-title":"Radiother Oncol"},{"key":"2021122308322525700_B46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.radonc.2008.05.020","article-title":"A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision","volume":"88","author":"Davey","year":"2008","journal-title":"Radiother Oncol"},{"key":"2021122308322525700_B47","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ijrobp.2009.05.032","article-title":"Randomized comparison of whole brain radiotherapy, 20 Gy in four daily fractions versus 40 Gy in 20 twice-daily fractions, for brain metastases","volume":"77","author":"Graham","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308322525700_B48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2004.00.1768","article-title":"Phase III study of Efaproxiral as an adjunct to whole brain radiation therapy for brain metastases","volume":"24","author":"Suh","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308322525700_B49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0360-3016(02)03217-0","article-title":"Whole brain radiotherapy alone or in combination with temozolomide for brain metastases. A phase III trial","volume":"54","author":"Antonadou","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308322525700_B50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lungcan.2004.02.019","article-title":"A randomized phase III study of palliative radiation with concomitant carboplatin for brain metastases from nonsmall cell carcinoma of the lung","volume":"46","author":"Guerrieri","year":"2004","journal-title":"Lung Cancer"},{"key":"2021122308322525700_B51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bjc.6604835","article-title":"A phase III trial of topotecan and whole brain radiation therapy for patients with CNS metastases due to lung cancer","volume":"100","author":"Neuhaus","year":"2009","journal-title":"Br J Cancer"},{"key":"2021122308322525700_B52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijrobp.2007.09.016","article-title":"A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118)","volume":"71","author":"Knisely","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308322525700_B53","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11060-008-9791-2","article-title":"Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients","volume":"93","author":"Chargari","year":"2009","journal-title":"J Neurooncol"},{"issue":"suppl 3","key":"2021122308322525700_B54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3171\/jns.2000.93.supplement_3.0032","article-title":"Gamma knife treatment for multiple metastatic brain tumors compared with whole-brain radiation therapy","volume":"93","author":"Serizawa","year":"2000","journal-title":"J Neurosurg"},{"key":"2021122308322525700_B55","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jocn.2008.08.003","article-title":"Gamma knife radiosurgery for multiple brain metastases from lung cancer","volume":"16","author":"Park","year":"2009","journal-title":"J Clin Neurosci"},{"issue":"suppl 3","key":"2021122308322525700_B56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3171\/jns.2000.93.supplement_3.0030","article-title":"Gamma knife radiosurgery for simultaneous multiple metastatic brain tumors","volume":"93","author":"Suzuki","year":"2000","journal-title":"J Neurosurg"},{"issue":"suppl","key":"2021122308322525700_B57","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3171\/jns.2002.97.supplement_5.0511","article-title":"Radiosurgery as palliation for brain metastases: A retrospective review of 72 patients harboring multiple lesions at presentation","volume":"97","author":"Amendola","year":"2002","journal-title":"J Neurosurg"},{"issue":"suppl","key":"2021122308322525700_B58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3171\/sup.2005.102.s_supplement.0147","article-title":"Gamma knife surgery for brain metastases in patients harboring four or more lesions: Survival and prognostic factors","volume":"102","author":"Nam","year":"2005","journal-title":"J Neurosurg"},{"key":"2021122308322525700_B59","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ijrobp.2005.08.035","article-title":"Stereotactic radiosurgery for four or more intracranial metastases","volume":"64","author":"Bhatnagar","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308322525700_B60","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3171\/2008.10.JNS08214","article-title":"Thirty years' experience with Gamma Knife surgery for metastases to the brain","volume":"111","author":"Karlsson","year":"2009","journal-title":"J Neurosurg"},{"issue":"suppl","key":"2021122308322525700_B61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3171\/2010.8.GKS10999","article-title":"Radiosurgery alone for 5 or more brain metastases: Expert opinion survey","volume":"113","author":"Knisely","year":"2010","journal-title":"J Neurosurg"},{"key":"2021122308322525700_B62","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijrobp.2010.06.057","article-title":"Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients","volume":"81","author":"Chargari","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl","key":"2021122308322525700_B63","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/jco.2010.28.15_suppl.1154","article-title":"Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer","volume":"28","author":"Lin","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308322525700_B64","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.1016\/j.ijrobp.2011.06.1968","article-title":"Relationship between HER2 status and prognosis in women with brain metastases from breast cancer","volume":"82","author":"Xu","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl","key":"2021122308322525700_B65","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1200\/jco.2005.23.16_suppl.637","article-title":"Impact of HER2 status in breast cancer patients receiving stereotactic radiosurgery for brain metastases","volume":"23","author":"O'Meara","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308322525700_B66","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/1097-0142(19860815)58:4<832::AID-CNCR2820580404>3.0.CO;2-W","article-title":"Chemotherapy induces regression of brain metastases in breast carcinoma","volume":"58","author":"Rosner","year":"1986","journal-title":"Cancer"},{"key":"2021122308322525700_B67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01053937","article-title":"Brain metastases in breast cancer; natural history, prognostic factors and outcome","volume":"15","author":"Boogerd","year":"1993","journal-title":"J Neurooncol"},{"key":"2021122308322525700_B68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11060-007-9409-0","article-title":"Capecitabine therapy of central nervous system metastases from breast cancer","volume":"85","author":"Ekenel","year":"2007","journal-title":"J Neurooncol"},{"key":"2021122308322525700_B69","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00432-012-1218-y","article-title":"Chemotherapy as primary treatment for brain metastases from breast cancer: Analysis of 115 one-year survivors","volume":"138","author":"Boogerd","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122308322525700_B70","first-page":"652","article-title":"New insights and emerging therapies for breast cancer brain metastases","volume":"26","author":"Lim","year":"2012","journal-title":"Oncology (Williston Park)"},{"key":"2021122308322525700_B71","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-005-9044-6","article-title":"Systemic high-dose intravenous methotrexate for central nervous system metastases","volume":"78","author":"Lassman","year":"2006","journal-title":"J Neurooncol"},{"key":"2021122308322525700_B72","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/annonc\/mdp343","article-title":"Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: A multicenter phase II study","volume":"21","author":"Siena","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122308322525700_B73","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-004-9176-0","article-title":"Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) Phase II study","volume":"71","author":"Christodoulou","year":"2005","journal-title":"J Neurooncol"},{"key":"2021122308322525700_B74","volume-title":"Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiotherapy (WBXRT)","author":"Murphy","year":"2009"},{"key":"2021122308322525700_B75","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.clbc.2011.03.024","article-title":"A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases","volume":"11","author":"Freedman","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"2021122308322525700_B76","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/annonc\/mdn036","article-title":"Defining prognosis for women with breast cancer and CNS metastases by HER2 status","volume":"19","author":"Dawood","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122308322525700_B77","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/1471-2407-11-395","article-title":"Brain metastases from breast cancer: Prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death","volume":"11","author":"Le Scodan","year":"2011","journal-title":"BMC Cancer"},{"key":"2021122308322525700_B78","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","article-title":"Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122308322525700_B79","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/jco.2008.26.15_suppl.1094","article-title":"Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU)","volume":"26","author":"Boccardo","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308322525700_B80","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.bjc.6605586","article-title":"Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastasesthe UK experience","volume":"102","author":"Sutherland","year":"2010","journal-title":"Br J Cancer"},{"key":"2021122308322525700_B81","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdq434","article-title":"Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine","volume":"22","author":"Metro","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122308322525700_B82","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11060-011-0629-y","article-title":"Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases","volume":"105","author":"Lin","year":"2011","journal-title":"J Neurooncol"},{"key":"2021122308322525700_B83","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/1471-2407-12-322","article-title":"Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: An open-label expanded access study in Korea","volume":"12","author":"Ro","year":"2012","journal-title":"BMC Cancer"},{"key":"2021122308322525700_B84","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1007\/s11095-009-9964-5","article-title":"Uptake of ANG1005, a novel paclitaxel derivative, through the blood\u2013brain barrier into brain and experimental brain metastases of breast cancer","volume":"26","author":"Thomas","year":"2009","journal-title":"Pharm Res"},{"key":"2021122308322525700_B85","volume-title":"ANG1005: Results of a Phase I study in patients with advanced solid tumors and brain metastases","author":"Sarantopoulos","year":"2011"},{"key":"2021122308322525700_B86","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.SABCS12-P3-12-04","volume-title":"A phase 2, multi-center, open label study evaluating the efficacy and safety of GRN1005 alone or in combination with trastuzumab in patients with brain metastases from breast cancer","author":"Lin","year":"2012"},{"key":"2021122308322525700_B87","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ijrobp.2009.06.030","article-title":"The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death","volume":"77","author":"Niwinska","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308322525700_B88","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ijrobp.2008.05.031","article-title":"Prophylactic cranial irradiation in advanced breast cancer: A case for caution","volume":"73","author":"Huang","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 9","key":"2021122308322525700_B89","first-page":"ixe1","article-title":"Cerebel (EGF111438): An open label randomized phase III study comparing the incidence of CNS metastases in patients with HER2+ metastatic breast cancer, treated with lapatinib plus capecitabine versus trastuzumab plus capecitabine","volume":"23","author":"Pivot","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122308322525700_B90","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/CCO.0b013e32833de986","article-title":"Leptomeningeal metastasis","volume":"22","author":"Chamberlain","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"2021122308322525700_B91","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-005-9044-6","article-title":"Systemic high-dose intravenous methotrexate for central nervous system metastases","volume":"78","author":"Lassman","year":"2006","journal-title":"J Neurooncol"},{"key":"2021122308322525700_B92","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1470-2045(06)70864-6","article-title":"Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab","volume":"7","author":"Platini","year":"2006","journal-title":"Lancet Oncol"},{"key":"2021122308322525700_B93","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/annonc\/mdn654","article-title":"High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer","volume":"19","author":"Mir","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122308322525700_B94","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.breast.2011.05.007","article-title":"Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis","volume":"20","author":"Mego","year":"2011","journal-title":"Breast"},{"key":"2021122308322525700_B95","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10549-011-1417-2","article-title":"Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab","volume":"127","author":"Oliveira","year":"2011","journal-title":"Breast Cancer Res Treat"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2012-0438","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0438","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/6\/675\/41856211\/oncolo_18_6_675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/6\/675\/41856211\/oncolo_18_6_675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T23:01:13Z","timestamp":1640300473000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/6\/675\/6410229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,1]]},"references-count":95,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,6,5]]},"published-print":{"date-parts":[[2013,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0438","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,6,1]]},"published":{"date-parts":[[2013,6,1]]}}}